By defining the transcription factors that regulate expression and potentially overexpression of α-synuclein that can lead to neurodegeneration, we will be able to identify targets for novel therapeutic approaches for α-synucleinopathies including Parkinson’s disease. This evidence concerns the gene SNCA and synucleinopathy.